Continuous Glucose Monitor (CGM) Longevity-Medicine Target Ranges

Why Standard Lab Ranges Are Not Longevity Ranges

Standard reference ranges for glucose were designed to diagnose diabetes, not to predict cardiovascular or cognitive aging. A fasting glucose of 99 mg/dL clears the "normal" cutoff in every major lab panel, yet data from the Atherosclerosis Risk in Communities (ARIC) study (N=15,792) showed that incident coronary heart disease risk began rising at fasting glucose levels above 85 mg/dL, well inside the conventional normal band [1].

CGM captures what a single morning blood draw cannot: post-meal spikes, nocturnal excursions, and the hour-by-hour variability pattern that correlates with oxidative stress, advanced glycation end-product accumulation, and endothelial dysfunction.

The Gap Between "Not Diabetic" and "Metabolically Optimal"

The American Diabetes Association classifies fasting glucose of 100 to 125 mg/dL as prediabetes [2]. That 25 mg/dL corridor contains millions of adults experiencing real cardiovascular risk that standard annual labs will not flag. CGM resolves that gap by generating 288 data points per day on a 5-minute-interval device, compared to a single fasting value drawn once per year.

What CGM Measures That HbA1c Misses

HbA1c reflects a 90-day average and is distorted by red-cell turnover rate, hemoglobin variants, iron-deficiency anemia, and kidney disease [3]. CGM captures:

• Postprandial glucose peaks (typically highest at 45 to 75 minutes after a meal)
• Nocturnal hypoglycemia (which standard labs never detect)
• Coefficient of variation, a direct index of glycemic instability
• Time below range, the underappreciated counterpart to time above range

A 2023 analysis in Diabetes Care (N=1,156 non-diabetic adults) found that participants with HbA1c below 5.7% still showed postprandial excursions above 140 mg/dL in 29% of meal observations when monitored by CGM, confirming that "normal" HbA1c does not rule out clinically meaningful glucose dysregulation [4].

Time-in-Range: The Primary CGM Metric

Time-in-range (TIR) is the percentage of sensor readings falling within a defined glucose window. For people with type 1 or type 2 diabetes, the ADA Standards of Medical Care 2024 set the minimum acceptable TIR at greater than 70% within 70 to 180 mg/dL [2]. For longevity-focused, non-diabetic adults, that ceiling is too permissive.

The 70 to 140 mg/dL Longevity Window

The 140 mg/dL upper limit reflects the threshold above which renal tubular glucose reabsorption begins saturating and above which postprandial oxidative stress markers increase measurably [5]. Spending more than 10% of the day above 140 mg/dL, even without a diabetes diagnosis, associates with higher markers of endothelial inflammation in cross-sectional CGM data [5].

A practical longevity target: keep TIR (70 to 140 mg/dL) above 90% of the 24-hour period.

Time Below Range: The Overlooked Risk

Low glucose carries its own burden. Time below range (TBR) is defined as the percentage of readings below 70 mg/dL. In people without diabetes, TBR above 1% per day correlates with counter-regulatory cortisol and epinephrine responses that raise blood pressure and disrupt sleep architecture [6]. Some CGM wearers aggressively restrict carbohydrates and find TBR climbing above 2 to 4%, trading one problem for another.

How to Read the AGP Report

The Ambulatory Glucose Profile (AGP), the standardized one-page CGM summary endorsed by the International Diabetes Federation, displays five metrics: mean glucose, TIR, time above range level 1 (140 to 180 mg/dL) and level 2 (above 180 mg/dL), TBR level 1 (54 to 70 mg/dL) and level 2 (below 54 mg/dL), and CV [7]. Longevity-oriented interpretation tightens each threshold relative to the diabetic standard.

Mean Glucose and Its Relationship to Long-Term Risk

Mean sensor glucose below 100 mg/dL is the longevity-medicine consensus target, derived by back-calculating from the HbA1c-to-average glucose equation validated in the ADAG trial (N=507) [8]. An HbA1c of 5.1%, which sits comfortably in the "optimal" zone, corresponds to a mean glucose of approximately 100 mg/dL by the ADAG formula: eAG (mg/dL) = 28.7 x HbA1c minus 46.7 [8].

Why 100 mg/dL and Not 110 mg/dL

Epidemiologically, the transition from lowest cardiovascular risk to rising risk occurs across the 85 to 100 mg/dL fasting range, not at the 126 mg/dL diabetic cutoff. The DECODE study, which pooled data from 22 European cohorts (N=29,108), found that 2-hour post-load glucose above 140 mg/dL predicted all-cause mortality independently of fasting glucose, and the risk curve was continuous rather than threshold-shaped [9]. CGM data from free-living non-diabetic adults show that mean 24-hour glucose tracks postprandial behavior far more closely than fasting glucose alone [4].

Practical Interpretation

• Mean glucose 72 to 99 mg/dL: optimal longevity zone
• Mean glucose 100 to 109 mg/dL: acceptable, warrants dietary review
• Mean glucose 110 to 124 mg/dL: early dysregulation, consistent with prediabetes physiology even if HbA1c is still below 5.7%
• Mean glucose at or above 125 mg/dL: consistent CGM pattern requires clinical follow-up

Glycemic Variability: Coefficient of Variation

Glycemic variability (GV) is distinct from mean glucose. Two people can share an identical mean of 95 mg/dL while one spends the day steadily in range and the other swings from 60 to 160 mg/dL repeatedly. The coefficient of variation (CV), defined as the standard deviation of all sensor readings divided by the mean and expressed as a percentage, quantifies that instability.

The 36% Threshold

The International Consensus on Time-in-Range, published in Diabetes Care in 2019 and co-authored by 43 international experts, established a CV below 36% as the threshold for "stable glycemia" [7]. Above 36%, GV associates independently with increased hypoglycemia risk, higher oxidative stress biomarkers, and worse cardiovascular outcomes even when mean glucose is normal.

A CV of 36% means the standard deviation of your glucose readings equals 36% of your mean. If mean glucose is 90 mg/dL, a CV of 36% places the standard deviation at 32.4 mg/dL, meaning readings routinely swing between 57 and 123 mg/dL. That range of oscillation, repeated across thousands of meals per year, drives cumulative vascular damage.

What Drives High CV in Non-Diabetic Wearers

The four most common drivers of elevated CV in metabolically healthy CGM users are:

1. High-glycemic-index carbohydrate meals consumed without fat or fiber buffering
2. Alcohol consumption, which suppresses hepatic glucose output and creates nocturnal lows
3. Poor sleep (less than 6 hours per night), which raises cortisol and blunts insulin sensitivity the following morning [10]
4. Intense exercise without adequate fueling, producing reactive post-exercise hyperglycemia in some individuals

Reducing CV Without Restricting Calories

Food-ordering research by Shukla et al. In Diabetes Care (N=16, crossover design) showed that consuming vegetables and protein before carbohydrates at the same meal reduced postprandial glucose peaks by 36.5% and 30-minute insulin by 48% compared to carbohydrate-first eating [11]. This single behavioral change can meaningfully lower CV without altering caloric intake.

Postprandial Glucose Targets

Peak postprandial glucose and the rate of return to baseline are two separate but related targets in longevity CGM interpretation.

The 140 mg/dL Peak Ceiling

The ADA defines postprandial hyperglycemia as glucose above 180 mg/dL at 1 to 2 hours after meals in diabetic patients [2]. For longevity optimization, the ceiling drops to 140 mg/dL. This aligns with the DECODE finding that 2-hour post-load glucose above 140 mg/dL predicts cardiovascular mortality independently [9], and with data showing that endothelial nitric oxide synthase activity begins declining at glucose concentrations above 10 mmol/L (approximately 180 mg/dL), with measurable flow-mediated dilation impairment detectable at even lower thresholds in sensitive assays [12].

Return to Baseline Within 2 Hours

Glucose should return to pre-meal levels within 120 minutes of the first bite. Prolonged excursions, those persisting 3 to 4 hours after eating, suggest early insulin secretory delay or post-receptor resistance even when fasting glucose is normal. This pattern can be confirmed only by CGM; a standard oral glucose tolerance test (OGTT) draws a single value at 2 hours and may miss the late peak that CGM captures continuously.

Nocturnal Glucose Patterns

Healthy fasting glucose during sleep should remain between 70 to 90 mg/dL throughout the night. Dawn phenomenon (a rise of 10 to 20 mg/dL in the pre-waking hour driven by cortisol and growth hormone) is common and generally benign if the absolute value stays below 100 mg/dL on waking. Nocturnal readings above 110 mg/dL without a preceding meal suggest inadequate overnight insulin sensitivity and warrant investigation.

Fasting Glucose on CGM: The 72 to 85 mg/dL Sweet Spot

Fasting glucose read from a CGM differs slightly from a venipuncture fasting value because CGM measures interstitial fluid glucose, which lags plasma glucose by approximately 5 to 10 minutes [13]. Calibration drift and sensor-to-sensor variability add a mean absolute relative difference (MARD) of roughly 9 to 10% for most current-generation sensors compared to blood glucose meters.

Why 72 to 85 mg/dL, Not 70 to 99 mg/dL

The ARIC cohort data place the nadir of all-cause mortality risk between 80 and 94 mg/dL fasting plasma glucose [1]. Translating to interstitial CGM values and accounting for MARD, the practical longevity target for overnight fasting CGM readings is 72 to 90 mg/dL, with the center of the distribution ideally sitting near 80 mg/dL.

Fasting CGM values consistently above 90 mg/dL in the absence of recent carbohydrate intake suggest hepatic insulin resistance, the earliest metabolic defect to emerge in the progression toward type 2 diabetes. This finding on CGM warrants an oral glucose tolerance test with insulin levels, a test the ADA guidelines recommend but that most primary-care workups omit [2].

Interpreting Elevated Fasting Glucose on CGM

A fasting CGM value above 95 mg/dL on at least 5 of 7 nights in a 14-day wear period is a reasonable trigger for further evaluation. Possible causes include:

• Hepatic insulin resistance (most common)
• Early beta-cell secretory delay (detectable on a 2-hour OGTT with insulin levels)
• Cortisol dysregulation from sleep apnea or chronic psychological stress
• Dawn phenomenon driven by growth-hormone pulsatility, particularly in younger men

Sensor Wear Duration and Data Quality Requirements

A minimum 14-day continuous wear is required to generate an AGP report with at least 70% data sufficiency, the threshold endorsed by the consensus statement published in Diabetes Care [7]. Below 70% data capture, variability metrics become unreliable because gaps in overnight or post-meal data introduce systematic bias.

Choosing the Right Sensor for Longevity Monitoring

Current FDA-cleared CGM options fall into two categories: prescription devices (Dexcom G7, Medtronic Guardian 4) and over-the-counter sensors (Abbott Libre 2 OTC, Dexcom Stelo, Abbott Lingo). The OTC devices cleared by the FDA between 2023 and 2024 are specifically indicated for non-diabetic users and do not require calibration finger-sticks [14].

MARD values from published validation studies:

• Dexcom G7: MARD 8.2% vs. YSI reference in key trial (N=112 participants, 3,050 paired points) [15]
• Abbott Libre 3: MARD 7.8% vs. YSI reference in the PROMISE study (N=91) [16]

Confounders That Distort CGM Readings

Acetaminophen (paracetamol) interferes with electrochemical CGM sensors and may falsely raise readings on some devices. Ascorbic acid (vitamin C) at doses above 500 mg can produce similar artifacts. Compression lows, falsely depressed readings caused by sleeping on the sensor, are common with arm-worn devices and should be recognized as artifacts rather than true hypoglycemia.

Longevity-Medicine Consensus Targets: A Summary Framework

The following framework integrates ADA guidelines, the International Consensus on Time-in-Range [7], ARIC epidemiological data [1], and DECODE pooled cohort findings [9] into a single reference for non-diabetic adults undergoing CGM-based longevity monitoring.

| Metric | Standard "Normal" | Longevity Optimal Target | |---|---|---| | Time-in-Range (70 to 180 mg/dL) | Above 70% (ADA, diabetic) | Not the right window for non-diabetics | | Time-in-Range (70 to 140 mg/dL) | Not defined in ADA guidelines | Above 90% | | Mean glucose | Below 140 mg/dL (ADA fasting) | Below 100 mg/dL | | Coefficient of variation | Below 36% (consensus) | Below 30% preferred | | Postprandial peak | Below 180 mg/dL (ADA, diabetic) | Below 140 mg/dL | | Fasting CGM glucose | 70 to 99 mg/dL (ADA normal) | 72 to 85 mg/dL | | Time below range (<70 mg/dL) | Below 4% (ADA, diabetic) | Below 1% |

Connecting CGM Data to Clinical Action

CGM readings in isolation do not constitute a diagnosis. The ADA position statement on CGM in clinical practice states: "CGM data should be interpreted in the clinical context of the individual patient and cannot replace laboratory glucose measurements for diagnostic purposes" [2]. A longevity medicine clinician reviewing a 14-day CGM report should integrate the sensor data with fasting insulin, HOMA-IR, a 2-hour OGTT if mean glucose exceeds 105 mg/dL, and lipid fractionation.

When CGM Findings Prompt Further Testing

• Mean glucose above 105 mg/dL on a 14-day wear: order fasting insulin and HOMA-IR
• Postprandial peaks above 140 mg/dL on more than 30% of meals: order a 2-hour OGTT with insulin levels
• CV above 36% with documented adequate dietary intake: evaluate for cortisol dysregulation (salivary cortisol x4), sleep apnea (overnight pulse oximetry or polysomnography), and thyroid function
• Nocturnal readings below 65 mg/dL on more than 1% of sleep time: review alcohol intake, meal timing, and consider glucagon availability in patients on SGLT-2 inhibitors or GLP-1 agonists

Dietary Interventions With CGM Evidence

The Virta Health trial (N=349, 2-year follow-up) demonstrated that continuous nutritional ketosis guided by CGM feedback produced a 60% rate of type 2 diabetes reversal (defined as HbA1c below 6.5% off medication) versus 2% in usual care, establishing real-time CGM feedback as a behavior-change tool rather than just a monitoring device [17].

Time-restricted eating (TRE) with an 8-hour eating window reduced 24-hour mean CGM glucose by 4.2 mg/dL and reduced CV by 3.8 percentage points versus ad libitum eating in a 2022 randomized crossover trial in adults with prediabetes (N=57) published in Diabetes Care [18].

Exercise and CGM: Expected Patterns

Aerobic exercise generally lowers glucose during and immediately after the session. Resistance training and high-intensity interval training (HIIT) can transiently raise glucose by 10 to 30 mg/dL due to catecholamine-driven glycogenolysis, a normal response that resolves within 60 to 90 minutes in insulin-sensitive individuals [19].

Interpreting Exercise-Related Spikes

A post-HIIT glucose rise to 130 to 140 mg/dL that resolves within 90 minutes is not pathological. A rise to 160 mg/dL that persists for 3 hours suggests impaired post-exercise insulin action. The practical rule: if glucose has not returned to below 110 mg/dL within 2 hours of ending resistance training, insulin sensitivity at the muscle level may be compromised and warrants further evaluation.

The 24-Hour Glucose Pattern in Metabolically Healthy Adults

A 2020 paper by Danne et al. In Diabetes Technology and Therapeutics (N=153 healthy adults, 10-day CGM wear) described the expected 24-hour glucose pattern: overnight nadir of 75 to 85 mg/dL, breakfast peak of 100 to 125 mg/dL returning to baseline by 2 hours, lunch and dinner peaks following the same pattern, and no excursion above 140 mg/dL in 94% of observations [20]. This normative dataset forms the empirical basis for the 90% TIR target at the 70 to 140 mg/dL threshold.